SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Politics : The Trump Presidency
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
Recommended by:
bentway
To: i-node who wrote (164617)5/19/2020 6:23:13 AM
From: Lane31 Recommendation  Read Replies (2) of 361409
 
Pretty sure this is done routinely.

We absolutely do not routinely conduct trials that require both experimental and control group to be purposely exposed to something potentially damaging, even deadly.

"Routine" trials are designed around sick people and a drug that could potentially render them unsick. The risk to the experimental participants is mostly disappointment, possible previously undetected side effects. The risk to the control group, negligible.

A trial for a prophylactic for a deadly disease, OTOH, is not just the opposite of what we do routinely but a different paradigm. The participants in both groups are healthy. The object would be for the participants in the control group to experience more negative effects than the participants in the experimental group. Success would present as having caused greater harm to the control group than to the experimental group.

So, how would you get volunteers for your trial and would the trial be ethical?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News